最近，Markowska 等的一篇文章阐明了Galectin-3 介导血管生成的可能机制。这些作者发现，Galectin-3 参与了血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）诱导的血管生成。通过小干扰RNA 降低HUVEC 中Galectin-3 的表达，减少了VEGF 和bFGF 介导的迁移和毛细 ...

本研究首次揭示Galectin-9(Gal-9)在妊娠糖尿病(GDM)中的双重作用：临床观察显示孕妇血浆Gal-9水平与胎儿巨大儿呈正相关，而动物实验证实Gal-9缺失通过Tim-3+trNK细胞凋亡减少导致胎盘异常增殖和自噬障碍。该发现为GDM的早期预测和干预提供了新靶点，发表于《Scientific ...

半乳糖凝集素-3(Galectin-3，Gal-3)是氧化应激的标志，在PF的发病机制中起着关键作用。成纤维细胞-肌成纤维细胞分化(FMD)是PF中纤维细胞的重要来源。

铁死亡肿瘤细胞通过分泌 Galectin-13 与邻近肿瘤细胞膜上的 CD44 结合来抑制 SLC7A11 的质膜定位，增强邻近肿瘤细胞铁死亡敏感性，从而引发铁死亡传播。

Galectin–glycoprotein interactions form a multivalent 'lattice' that controls glycoprotein clustering and endocytosis to regulate receptor signalling and activation. Several members of the ...

近日，北京大学第三医院肖晗课题组在Science China Life Sciences发表了题为“Galectin-3-centered paracrine networkmediates cardiac inflammation and fibrosis upon β-adrenergic ...

胶质母细胞瘤（GBM）是最常见的恶性原发性脑肿瘤，目前其治疗方案为最大范围手术切除及术后同步放化疗，但预后仍不理想，病人中位生存期仅 14 ...

Galectin Therapeutics Inc. NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading ...

Dec. 20, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its global clinical ...

NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results ...

Galectin Therapeutics (GALT) announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis cirrhosis and portal ...